Article
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
Leukemia - 1 Nov 2015
Molenaar R J, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, Hirsh C, Viny A D, Hosano N, Bleeker F E, Meggendorfer M, Alpermann T, Shiraishi Y, Chiba K, Tanaka H, van Noorden C J F, Radivoyevitch T, Carraway H E, Makishima H, Miyano S, Sekeres M A, Ogawa S, Haferlach T, Maciejewski J P
Abstract excerpt
Mutations in isocitrate dehydrogenase 1/2 (IDH1/2(MT)) are drivers of a variety of myeloid neoplasms. As they yield the same oncometabolite, D-2-hydroxyglutarate, they are often treated as equivalent, and pooled. We studied the validity of this approach and found IDH1/2 mutations in 179 of 2119 myeloid neoplasms (8%). Cross-sectionally, the frequencies of these mutations increased from lower- to higher risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.